This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Atherogenics Is Feeling the Squeeze

When a clinical trial gives you lemons, try to make lemonade.

That's what Atherogenics (AGIX) did Tuesday with results from a phase III trial of its heart drug AGI-1067. The company downplayed that the study failed to meet its primary endpoint in a spectacular fashion; instead, it focused on a hodgepodge of positive secondary endpoints.

But in this case, Atherogenics' glass of lemonade might be the last one the company squeezes since the phase III trial turned up some potentially serious side effects associated with AGI-1067, most notably liver toxicity, which has meant the end for drugs in the past.

Atherogenics traded in the green most of the day, but concerns over AGI-1067's safety forced the stock lower in the afternoon session. The stock closed down 34 cents, or 9.5%, to $3.24. After hours, shares fell another 4% to $3.11.

The phase III data from the ARISE trial of AGI-1067 was presented Tuesday at the annual meeting of the American College of Cardiology.

AGI-1067 is a pill designed to break down and reduce the level of fatty plaque deposits in a person's arteries. Clearer arteries are healthier arteries and should lower the risk of cardiovascular illnesses such as heart attacks and strokes and reduce the need for additional surgery to reopen arteries.

The ARISE trial enrolled more than 6,100 patients with heart disease and tested the effect of AGI-1067 vs. placebo on the time to first incidence of a composite of major cardiovascular events, such as cardiovascular death, heart attack, stroke, need for coronary revascularization and unstable angina.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AZN $29.15 0.00%
AAPL $93.70 0.00%
FB $101.91 0.00%
GOOG $683.11 0.00%
TSLA $150.47 0.00%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs